: Scotts Miracle-Gro says cannabis slowdown and supply chain problems impacted sales

This post was originally published on this site

Scotts Miracle-Gro Co. said Tuesday that it is maintaining its full-year adjusted earnings outlook, though the company expects a 40% decline in Hawthorne sales during the fiscal first quarter due to a slowdown in the cannabis market and supply chain issues. The fiscal first quarter ended January 1.

Hawthorne is a wholly-owned subsidiary of Scotts Miracle-Gro
SMG,
-2.95%

specializing in items for indoor and hydroponic growing.

Adjusted earnings for the fiscal year are expected to be in the range of $8.50 to $8.90.

The FactSet consensus is for full-year sales of $4.9 billion and EPS of $8.58.

See: Investors in cannabis companies burned by stock-market losses in 2021 even as the pot business grows

Chief Financial Officer Cory Miller said in a statement that the company expects the supply chain problems to be resolved by the end of January and pre-orders for the second and third quarters are healthy.

“However, the decline we’ve seen in the first quarter, against a 71% growth comparison a year ago, is greater than we had anticipated. Based on our current view of the market, we are lowering our full-year sales guidance for Hawthorne to a range of 0 to minus 10% on a year-over-year basis,” he said.

Scotts Miracle-Gro also announced two acquisitions on Tuesday: Luxx Lighting for $215 million, and True Liberty Bags, a liners and storage company for the hydroponic market, for $10 million.

Scotts says Luxx will add $100 million in sales and $20 million in operating income annually to Hawthorne’s business. Luxx is expected to generate $75 million in sales for the remainder of fiscal 2022, and is expected to be earnings neutral for the first year. Hawthorne’s full-year sales guidance includes consideration of the Luxx acquisition, and “assumes a return to growth during the second half of the year,” Miller said.

Want intel on all the news moving markets before the day starts? Sign up for our daily Need to Know newsletter.

Raymond James analysts followed by reiterating their strong buy rating on Scotts’ stock but by shaving $5 from the price target, bringing it to $195.

“Our strong buy rating on the shares of Scotts Miracle-Gro reflects both our long-term optimism regarding the company’s Hawthorne hydroponics segment, as well as our view that much of the recent expansion in the addressable market for its U.S.,” wrote Raymond James in a note. “Consumer segment during the COVID pandemic should prove sustainable.”

Scotts announced in August 2021 that it had acquired HydroLogic Purification Systems in a $65 million deal and Rhizoflora, a nutrient company that was added to the Hawthorne portfolio.

Scotts Miracle-Gro is scheduled to host its annual meeting on Jan. 24 and announce first-quarter results on Feb. 1, according to a FactSet calendar.

Scotts Miracle-Gro stock fell 2.1% in Tuesday trading, and has slumped 19.7% over the last year.

The S&P 500 index
SPX,
-0.36%

has gained 29.4% over the period.